SEELQ (Seelos Therapeutics) E10: $-152,958.13 (As of Jun. 2024)


SEELQ Seelos Therapeutics Inc SEELQ
16 GF Score
Price $0.00
View Full Analysis

What is Seelos Therapeutics E10?

Seelos Therapeutics SEELQ 16 E10 is $-152,958.13 as of Jun. 2024. GuruFocus rates SEELQ with a GF Score™ of 16/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Seelos Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2024 was $1.920. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-152,958.13 for the trailing ten years ended in Jun. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-30), Seelos Therapeutics's current stock price is $0.0001. Seelos Therapeutics's E10 for the quarter that ended in Jun. 2024 was $-152,958.13. Seelos Therapeutics's Shiller PE Ratio of today is .


Seelos Therapeutics  (OTCPK:SEELQ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Seelos Therapeutics E10 Related Terms


Seelos Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Seelos Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seelos Therapeutics E10 Chart

Seelos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -792,361.77 -466,575.27 -369,796.12 -225,383.67 -155,251.78

Seelos Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -172,036.22 -161,331.71 -155,251.78 -144,607.46 -152,958.13

SEELQ vs NTBLQ, EFTR, MTEM: E10 Comparison

For the Biotechnology subindustry, Seelos Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seelos Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's Shiller PE Ratio falls into.


SEELQ
16GF Score
Seelos Therapeutics Inc SEELQ
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seelos Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Seelos Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.92/314.1750*314.1750
=1.920

Current CPI (Jun. 2024) = 314.1750.

Seelos Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201409 -92,160.922 238.031 -121,642.381
201412 -460,804.609 234.812 -616,549.785
201503 -149,116.279 236.119 -198,411.000
201506 -121,976.744 238.638 -160,586.510
201509 -117,069.767 237.945 -154,575.192
201512 -54,232.558 236.525 -72,036.841
201603 -47,264.151 238.132 -62,357.074
201606 -62,981.132 241.018 -82,098.006
201609 -19,268.657 241.428 -25,074.682
201612 -4,462.687 241.432 -5,807.286
201703 120,492.537 243.801 155,273.124
201706 -13,400.000 244.955 -17,186.606
201709 -29,476.923 246.819 -37,521.067
201712 -18,530.303 246.524 -23,615.380
201803 -16,106.383 249.554 -20,277.066
201806 -11,216.749 251.989 -13,984.825
201809 -4,495.902 252.439 -5,595.411
201812 -28,518.367 251.233 -35,663.141
201903 -15,283.200 254.202 -18,888.913
201906 -345.600 256.143 -423.899
201909 -499.200 256.759 -610.830
201912 -1,514.493 256.974 -1,851.611
202003 -537.600 258.115 -654.361
202006 -307.200 257.797 -374.382
202009 -345.600 260.280 -417.162
202012 -499.200 260.474 -602.118
202103 -1,075.200 264.877 -1,275.313
202106 -384.000 271.696 -444.037
202109 -422.400 274.310 -483.787
202112 -1,075.200 278.802 -1,211.616
202203 -499.200 287.504 -545.509
202206 -768.000 296.311 -814.301
202209 -691.200 296.808 -731.644
202212 -657.920 296.797 -696.442
202303 -458.240 301.836 -476.973
202306 -858.560 305.109 -884.071
202309 -460.800 307.789 -470.361
202312 8.960 306.746 9.177
202403 -25.600 312.332 -25.751
202406 1.920 314.175 1.920

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-152,958.13 mean?
Seelos Therapeutics (SEELQ) has a E10 of $-152,958.13 as of Jun. 2024. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Seelos Therapeutics and its competitors.
Is Seelos Therapeutics' E10 too high?
Seelos Therapeutics' current E10 is $-152,958.13. Overall, Seelos Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Seelos Therapeutics' E10 compare to NTBLQ and EFTR?
Seelos Therapeutics' E10 of $-152,958.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Seelos Therapeutics and its competitors. Seelos Therapeutics's current E10 is $-152,958.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seelos Therapeutics stock overvalued right now?
Seelos Therapeutics (SEELQ) has a current E10 of $-152,958.13. The current E10 is $-152,958.13. Seelos Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Seelos Therapeutics (SEELQ), the current E10 is $-152,958.13 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seelos Therapeutics Business Description

Address 300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.
16GF Score

Get the complete analysis for SEELQ

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price